Abstract

ABSTRACTSalmonella is the leading cause of typhoidal and non-typhoidal infections in the world. The entry of Salmonella into the bloodstream causes an invasive disease state, resulting to high morbidity and mortality rates, especially in children. Owing to the misuse of antibiotics, certain Salmonella serovars are multi-drug resistant and do not respond to traditional antibiotics, such as ampicillin and trimethoprim-sulphamethoxazole, presenting a significant challenge for healthcare practitioners in treating and controlling the spread of this disease. Therefore, expensive third-generation cephalosporins, such as ceftriaxone, are currently used to treat Salmonella infection. However, a novel serovar of Salmonella that resists ceftriaxone was recently identified in Saudi Arabia, indicating wide spread Salmonella resistance. A comprehensive literature review on ceftriaxone resistance in Salmonella is therefore necessary to reflect upon current challenges. In this report, we provide a summary of Salmonella incidence, mechanisms of ceftriaxone resistance in Salmonella, and current treatment options.

Highlights

  • Infectious diseases remain a major cause of morbidity and mortality

  • This study provides strong evidence that ceftriaxone resistance is expressed in different clinical Salmonella isolates (15.3%) from Indian labor in Saudi Arabia

  • We present the challenges of ceftriaxone resistance in Salmonella with other treatment options

Read more

Summary

Introduction

Infectious diseases remain a major cause of morbidity and mortality. The rising numbers of pathogens, Salmonella that have developed resistance to a wide range of treatment options have been widely studied (Davies and Davies 2010). KEYWORDS Salmonella; typhoid fever; non-typhoid infections; drug resistance; ceftriaxone; cephalosporin Africa has the highest incidence rate of nontyphoidal Salmonella infections, and a troubling link between invasive non-typhoidal Salmonella disease, malaria and HIV has emerged (Smith et al 2016).

Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call